Correction: Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population (Cancer Research (2016) 76 (440–452) DOI: 10.1158/0008-5472.CAN-15-1640-T);Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population

Cancer Research

Volumn 76, Issue 2, 2016, Pages 440-452

  Bhola, Neil E ^a   Jansen, Valerie M ^a   Koch, James P ^a   Li, Hua ^b   Formisano, Luigi ^a   Williams, Janice A ^c   Grandis, Jennifer R ^b   Arteaga, Carlos L ^a,c,d  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUPARLISIB; DACTOLISIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HERMES ANTIGEN; INITIATION FACTOR 4E BINDING PROTEIN 1; JAGGED1; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MLN 128; MUCIN 1; MYC PROTEIN; NOTCH1 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; S6 KINASE; UNCLASSIFIED DRUG; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; CANCER STEM CELL; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958999543     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-4087     Document Type: Erratum

References (41)

1. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123: 236-40.
2. Liedtke C,Mazouni C, Hess K, Andre F, Tordai A,Mejia J, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
3. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-9.
4. Lehmann BD, Bauer JA, Chen X, SandersME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
5. Shah S, Morin R, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
6. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
7. Györffy B, Lanczky A, Eklund A, Denkert C, Budczies J, LiQ, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis usingmicroarray data of 1,809 patients. BreastCancer Res Treat 2010;123:725-31.
8. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 2014;15: 155-62.
9. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015;15:7-24.
10. Zhang H, Cohen A, Krishnakumar S, Wapnir I, Veeriah S, Deng G, et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res 2014;16:R36.
11. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Müller U, et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012;22:796-811.
12. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci 2011;108:E699-E708.
13. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, et al. The dual PI3K/mTORinhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 2011;6:e25132.
14. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVPBEZ235 compared to rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628-38.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
16. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol 2010;4:404-19.
17. Yu X, Alder JK, Chun JH, Friedman AD, Heimfeld S, Cheng L, et al. HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells 2006;24:876-88.
18. Saxena MT, Schroeter EH, Mumm JS, Kopan R. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. J Biol Chem 2001;276: 40268-73.
19. Bhola NE, Balko JM, Dugger TC, Kuba G, Sanchez V, Sanders M, et al. TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013;123:1348-58.
20. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
21. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583-94.
22. Xin H-W, Hari DM, Mullinax JE, Ambe CM, Koizumi T, Ray S, et al. Tumorinitiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012;30:591-8.
23. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59.
24. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N,MarchesiniM, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014;514:628-32.
25. Ngo HB, Lovely GA, Phillips R, Chan DC. Distinct structural features of TFAM drive mitochondrial DNA packaging versus transcriptional activation. Nat Commun 2014;5: 3077.
26. Yoshida M, Muneyuki E, Hisabori T. ATP synthase - a marvellous rotary engine of the cell. Nat Rev Mol Cell Biol 2001;2:669-77.
27. Bello E, ColellaG, Scarlato V, Oliva P, Berndt A, ValbusaG, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011;71:1396-405.
28. Soria J-C, DeBraud F, Bahleda R, Adamo B, Andre F, Dientsmann R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014;25:2244-51.
29. Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2009;2:ra75.
30. Stuhlmiller Timothy J, Miller Samantha M, Zawistowski Jon S, Nakamura K, Beltran Adriana S, Duncan James S, et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep 2015;11:390-404.
31. JohnstonO, Rose CL, Webster AC, Gill JS. Sirolimus is associated with newonset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19: 1411-8.
32. Hamanaka RB, Glasauer A, Hoover P, Yang S, Blatt H, Mullen AR, et al. Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development. Sci Signal 2013;6:ra8.
33. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
34. Hitosugi T, Fan J, Chung T-W, Lythgoe K, Wang X, Xie J, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 2011;44:864-77.
35. Chioni A-M, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol 2012;197:801-17.
36. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
37. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables cell plasticity and enhances tumorigenicity. Cell 2013;154:61-74.
38. Hwang-Verslues WW, Kuo W-H, Chang P-H, Pan C-C, Wang H-H, Tsai S-T, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 2009;4:e8377.
39. Yoon C-H, Kim M-J, Lee H, Kim R-K, Lim E-J, Yoo K-C, et al. PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem 2012;287:19516-27.
40. Lang J-Y, Hsu Jennifer L, Meric-Bernstam F, Chang C-J, Wang Q, Bao Y, et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011;20:341-56.
41. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71: 3991-4001.